Evidence map›Paper›PMID 40255263›Full record

ArticleIn silico pharmacology2025

Computational repurposing of polyphenols for anti-Mpoxviral activity.

Rishi Vachaspathy Astakala, Gagan Preet, Ahlam Haj Hasan, Ria Desai, Meshari Alfurayh, Rainer Ebel, Marcel Jaspars

Abstract read
In one paragraph

Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rishi Vachaspathy AstakalaMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.
Gagan PreetMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.
Ahlam Haj HasanMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.
Ria DesaiMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.
Meshari AlfurayhMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.
Rainer EbelMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.
Marcel JasparsMarine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Scotland, AB24 3FX UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mpox is a globally prevalent disease that has triggered multiple epidemics over the past few decades, leading to moderate rates of hospitalisation and mortality. Recently, it has re-emerged in several countries, including the Democratic Republic of Congo, and appears to be spreading at an unprecedented pace. The disease is caused by zoonotic double-stranded DNA viruses. Due to its similarities with smallpox, distinguishing between the two can be challenging, though the smallpox vaccine typically provides immunity against Mpox. At the time of writing, no approved treatment for Mpox exists; however, several promising candidates have demonstrated the ability to inhibit viral replication, including resveratrol-a polyphenolic compound found in red wine. This study employs molecular docking and molecular dynamics simulations to assess the effectiveness and stability of nine resveratrol analogues. Additionally, 2D and 3D pharmacophore models were developed for the highest-ranked docked compounds, leading to a composite pharmacophore. A structure-activity relationship analysis was also conducted using these top-performing compounds. The findings suggest that two compounds- ( Graphical abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00345-1.

Indexed as

Molecular dynamicsMpoxOrthopoxvirusPharmacophorePolyphenolsStructure–activity relationshipVirtual screening

Identifiers

PMID40255263
PMCPMC12006622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.